Oncogenic mutant K-Ras are found in ∼88% pancreatic, ∼50% colorectal, and ∼30% of lung cancers (Prior et al, 2020), and a group of newly developed K-Ras G12C direct inhibitors have shown promise in clinical trials. The gene discussed is KRAS; the disease is lung carcinoma.